Advanced Medical Optics Highlights Key Educational Courses at the American Society of Cataract and Refractive Surgery (ASCRS) An

Advanced Medical Optics Highlights Key Educational Courses at the
American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium
AMO Also to Launch New Multifocal IOL and Delivery System 


SANTA ANA, Calif., April 13  /PRNewswire-FirstCall/ -- Advanced Medical Optics,
Inc. (AMO) (NYSE:AVO), a global leader in ophthalmic surgical devices and eye
care products, today announced several educational courses and presentations at
the American Society of Cataract and Refractive Surgery (ASCRS) annual
symposium April 16 - 19, 2005, in Washington, DC.  The courses highlight AMO's
commitment to continuing education and technology.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO)

There are a total of 37 scheduled doctor presentations and panel discussions
covering AMO's cataract and refractive technologies including the ReZoom(TM),
Tecnis(R) and Verisyse(TM) IOLs, Amadeus(TM) II microkeratome and
StabilEyes(TM) capsular tension ring, among others.

Some of the scheduled educational courses include:

"An Update on Multifocal Intraocular Lens Use in Refractive Cataract Surgery"

Randall Olson, M.D. will instruct a course that will discuss considerations for
use of multifocal lenses in the evolving field of cataract/refractive surgery. 
Topics include patient selection, biometry, limbal-relaxing incisions, and
multifocal IOL advancements.

"Bimanual Micro-Phaco Cataract Surgery"

Roger Steinert, M.D. will instruct a course that will review the basics and
introduce latest innovations in bimanual micro-phacoemulsification. Topics
include transition to sleeveless bimanual micro-phaco; machine settings and
instrumentation; complications and management; and clinical pearls.

"Breakthroughs in Improving Functional Vision after Cataract Surgery"

Mark Packer, M.D. will instruct a course to discuss innovations in
measuring/improving functional vision in elderly post-phacoemulsification
patients, safety benefits, optic design, spherical aberration, and Wavefront
analysis.

In addition to these and other educational courses, AMO will host a series of
booth presentations on its refractive, cataract and glaucoma surgical
technologies.

For a complete schedule of AMO's educational courses and booth presentations,
please contact AMO or visit the AMO booth during the academy meeting.  AMO will
be located in booth #943 at the Washington Convention Center.

AMO will also introduce two new innovative products at the ASCRS symposium,
including the ReZoom(TM) IOL, a new design and next generation acrylic
three-piece multifocal IOL that was recently approved by the U.S. Food and Drug
Administration (FDA), and the Emerald XL Unfolder(TM) implantation system.  The
ReZoom(TM) IOL with Balanced View Optics(TM) technology distributes light over
five optical zones for enhanced restoration of visual function, providing
distance, intermediate and near vision for reduced spectacle dependence.

AMO's Emerald XL Unfolder(TM) system is used to implant the Sensar(R) acrylic
IOL with OptiEdge(TM) design.  The Emerald XL Unfolder(TM) implantation system
offers increased control and easier rotation because of its smaller threads and
larger wheel.  Physicians can still insert a three- piece 6-mm optic acrylic
IOL through an unenlarged phaco incision as small as 2.8 mm.

Along with the ReZoom(TM) IOL and Emerald XL Unfolder(TM) system, AMO will
spotlight its core surgical brands in booth #943 at the ASCRS symposium,
including the Sovereign(R) phaco system with WhiteStar(TM) technology,
Verisyse(TM) and Tecnis(R) IOLs, Amadeus(TM) II microkeratome, Baerveldt(R)
glaucoma implant, and Healon(R) and Vitax(R) ophthalmic viscosurgical devices.

The ReZoom(TM) IOL is indicated for the visual correction of aphakia in adult
patients in whom a cataractous lens has been removed and who may benefit from
useful near vision without reading glasses and increased spectacle independence
across a range of distances.  These devices are intended to be placed in the
capsular bag.  Multifocal subjects should exercise caution when driving at
night or in poor visibility conditions.  For a complete listing of precautions,
warnings and adverse events, refer to the package insert.  Rx only.

About Advanced Medical Optics (AMO)

AMO is a global leader in the development, manufacturing and marketing of
ophthalmic surgical and eye care products.  The company focuses on developing a
broad suite of innovative technologies and devices to address a wide range of
eye disorders.  Products in the ophthalmic surgical line include intraocular
lenses, phacoemulsification systems, viscoelastics, microkeratomes and related
products used in cataract and refractive surgery.  AMO owns or has the rights
to such ophthalmic surgical product brands as ReZoom(TM), Phacoflex(R),
Clariflex(R), Array(R), Sensar(R), CeeOn(R), Tecnis(R) and Verisyse(TM)
intraocular lenses, Sovereign(R) and Sovereign(R) Compact(TM)
phacoemulsification systems with WhiteStar(TM) technology, Amadeus(TM) and
Amadeus(TM) II microkeratomes, Healon(R) and Vitrax(R) viscoelastics, and the
Baerveldt(R) glaucoma shunt.  Products in the contact lens care line include
disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting
drops.  Among the contact lens care product brands the company possesses are
COMPLETE(R) Moisture PLUS(TM), COMPLETE(R) Blink-N-Clean(R), Consept(R)F,
Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(R)
and blink(TM) branded products.  Amadeus is a licensed product of, and a
trademark of, SIS, Ltd.  OptiEdge(TM) is a registered trademark of Ocular
Sciences.  AMO is based in Santa Ana, California, and employs approximately
3,000 worldwide.  The company has operations in about 20 countries and markets
products in approximately 60 countries.  For more information, visit the
company's Web site at http://www.amo-inc.com/.

Forward-Looking Statements

Statements in this press release regarding new product benefits, and any other
statements that refer to AMO's estimated or anticipated future results are
forward-looking statements.  All forward-looking statements in this press
release reflect AMO's current analysis of existing trends and information and
represent AMO's judgment only as of the date of this press release.  Actual
results may differ from current expectations based on a number of factors
affecting AMO's businesses, including but not limited to unexpected changes in
competitive, regulatory and market conditions, AMO's ability to obtain adequate
product supply and product successful collaborative efforts, unexpected
litigation or intellectual property issues, and the uncertainties associated
with market acceptance of new products.  Therefore, the reader is cautioned not
to rely on these forward-looking statements.  AMO disclaims any intent or
obligation to update these forward-looking statements.

Additional information concerning these and other risk factors may be found in
previous financial press releases issued by AMO.  AMO's public periodic filings
with the Securities and Exchange Commission, including the discussion under the
heading "Certain Factors and Trends Affecting AMO and its Businesses" in AMO's
2004 Form 10-K filed in March 2005 include information concerning these and
other risk factors.  Copies of press releases and additional information about
AMO are available at http://www.amo-inc.com/, or you can contact the AMO
Investor Relations Department by calling 714-247-8348.

   Advanced Medical Optics, Inc.
   Investors:
   Sheree Aronson
   [phone]
   

   Media:
   Steve Chesterman
   [phone]
   

http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO

http://photoarchive.ap.org/

DATASOURCE: Advanced Medical Optics, Inc.



CONTACT:  Investors, Sheree Aronson, [phone],

; or Media, Steve Chesterman, [phone],

, both for of Advanced Medical Optics, Inc.



Web site:  http://www.amo-inc.com/ 

Copyright